RBC Capital lowered the firm’s price target on Acadia Healthcare to $94 from $99 but keeps an Outperform rating on the shares after its Q3 earnings. The company reported solid results driven by impressive topline growth, and its volumes continue to be strong with Acadia seeing minimal impact from Medicaid redeterminations, the analyst tells investors in a research note. RBC contends that strong rate growth is expected to continue for the company through the first quarter of 2024 before moderating back to normal levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACHC:
- Acadia Healthcare price target lowered to $77 from $80 at Mizuho
- Acadia Healthcare price target lowered to $86 from $90 at TD Cowen
- Acadia Healthcare sees FY23 adjusted EPS $3.33-$3.43, consensus $3.41
- Acadia Healthcare reports Q3 adjusted EPS 95c, consensus 89c
- Acadia Healthcare to pay $400M to settle Desert Hills litigation
